Orthofix pays $15M for eNeura options to acquire — 5 things to know

Written by Laura Dyrda | March 31, 2015 | Print  |

Orthofix secured options to acquire eNeura, a portable, non-invasive transcranial magnetic stimulation device for treating migraine headaches.

Here are five things to know:

 

1.Orthofix entered into an option agreement allowing the company an 18-month option to acquire eNeura, which received an FDA clearance for SpringTMS last May.

 

2. Orthofix will provide $15 million collateralized loan to support SpringTMS commercialization in the United States and Europe.

 

3. If Orthofix decides to purchase eNeura, the company will pay $65 million to consummate the merger and eNeura will repay Orthofix the unpaid principal payable under the loan.

 

4. Orthofix may also make future milestone and royalty payments to eNeura.

 

5. Wells Fargo is the financial advisor to eNeura.

 

More articles on orthopedic devices:
Zimmer gets European Commission's OK for Biomet acquisition after knee business sale—5 key notes
Stryker's new Ireland-based plant to create hundreds of jobs
North American orthobiologics market to reach $2.5B by 2019: 4 key trends

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months